Haosen Pharmaceuticals has developed into a modern and innovative pharmaceutical group integrating chemical and biological drug research
Haosen Pharmaceuticals has developed into a modern and innovative pharmaceutical group integrating chemical and biological drug research, pharmaceutical intermediates and API synthesis, preparation manufacturing and product sales. It is a national key high-tech enterprise, one of the top 20 of China's top 100 pharmaceutical enterprises, and one of the main R&D and production bases of anti-tumor and psychotropic drugs in China.
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
ResearchConsumer Staples, Healthcare, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchHealthcare, Industrials, Financials
Tech for Global, Globalization Footprints of the Established and the New
Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
Since the outbreak of COVID-19, new public health systems and advanced biotechnology have been swiftly hyped up. Genetron Health has been able to generate a surging revenue in these special social circumstances.
May 26, 2021 05:17 AM
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM